Document is current

Article History

Received: 23 April 2025

Accepted: 20 May 2025

First Online: 25 June 2025

Declarations

:

: P. Dimitriadis and I.L.M. Reijers reported financial interest in Signature Oncology, and will receive some possible revenues if the IFN-γ signature is being developed as clinical companion diagnostic. A.M. Menzies reported personal fees from BMS, MSD, Novartis, Roche, Pierre-Fabre, and QBiotics outside the submitted work. G.V. Long is consultant advisor for Agenus, Amgen, Array Biopharma, AstraZeneca, Bayer, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb, Evaxion, GI Innovation, Hexal AG (Sandoz Company), Highlight Therapeutics S.L., Immunocore, Innovent Biologics USA, IOBiotech, Iovance Biotherapeutics, MSD, Novartis, PHMR Ltd., Pierre-Fabre, Regeneron, Scancell, and SkylineDX B.V.. L.F.A.W. reported research funding from Bristol-Meyers-Squibb (paid to the Netherlands Cancer Institute). C.U. Blank reported grants from BMS, Novartis, NanoString, and 4SC; personal fees from BMS, MSD, Roche, Novartis, GSK, AZ, Pfizer, Lilly, GenMab, Pierre-Fabre, and Third Rock Ventures; and is a co-founder of and has stock ownership in Immagene BV and Signature Oncology outside the submitted work; in addition, C.U. Blank had patents (incl. submitted): WO 2021/177822 A1, N2027907, P091040NL2 pending.